• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Akanda Corp.

    5/20/24 1:41:12 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AKAN alert in real time by email
    6-K 1 ea0206529-6k_akanda.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2024

     

    Commission File Number:  001-41324

     

    AKANDA CORP.

    (Name of registrant)

     

    1a, 1b Learoyd Road 

    New Romney TN28 8XU, United Kingdom 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    ☒   Form 20-F          ☐   Form 40-F

     

     

     

     

     

     

    INFORMATION CONTAINED IN THIS FORM 6-K REPORT

     

    1st Closing of Registered Direct Offering

     

    On May 17, 2024, Akanda Corp., a corporation organized under the laws of the Province of Ontario (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor in connection with the issuance and sale by the Company in a registered direct offering (the “Offering”) of 2,491,381 of the Company’s Common Shares, no par value per share (the “Common Shares” and, such number of Common Shares issued and sold in the Offering, the “Offered Shares”), at a purchase price of $0.1031 per Offered Share, and 21,756,922 pre-funded warrants to purchase 21,756,922 Common Shares at a purchase price of each pre-funded warrant equal to the price at which one Common Share is sold in the Offering, minus $0.0001, and the exercise price of each pre-funded warrant is $0.0001 per share (the “Pre-Funded Warrants” and, such number of Pre-Funded Warrants issued and sold in the Offering, the “Offered Pre-Funded Warrants”), pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-276577) and a related base prospectus, together with the related prospectus supplement dated as of May 17, 2024 (such registration statement, base prospectus and prospectus supplement, collectively, the “Registration Statement”), filed with the Securities and Exchange Commission. The Pre-Funded Warrants were immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to certain beneficial ownership limitations as set forth in the Pre-Funded Warrant. All of the Pre-Funded Warrants have been exercised.

     

    Univest Securities, LLC (“Univest”) acted as financial advisor in connection with the Offering, and in consideration therefor the Company agreed to pay Univest a total cash fee of four percent of the gross proceeds or $100,000. The Company also reimbursed Univest for out-of-pocket expenses, including up to $10,000 legal counsel expenses.

     

    The gross proceeds from the Offering were approximately $2,500,000 before deducting Univest’s fees and other estimated expenses relating to the Offering. The Company intends to use the net proceeds from the Offering on capital expenditures, operating capacity, working capital, general corporate purposes and the refinancing or repayment of existing indebtedness and acquisitions of complementary products, technologies or businesses.

     

    The closing of the Offering occurred on May 17, 2024.

     

    2nd Closing of Registered Direct Offering

     

    On May 17, 2024, the Company entered into an additional Purchase Agreement with an accredited investor in connection with the issuance and sale by the Company in a subsequent registered direct offering (the “Subsequent Offering”) of 2,491,381 Offered Common Shares, at a purchase price of $0.1031 per Offered Share, and 12,057,600 Offered Pre-Funded Warrants, pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-276577) and a related base prospectus, together with the related prospectus supplement dated as of May 20, 2024, filed with the Securities and Exchange Commission. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to certain beneficial ownership limitations as set forth in the Pre-Funded Warrant.

     

    Univest Securities, LLC (“Univest”) acted as financial advisor in connection with the Subsequent Offering, and in consideration therefor the Company agreed to pay Univest a total cash fee of four percent of the gross proceeds or $60,000. The Company will also reimburse Univest for out-of-pocket expenses, including up to $10,000 legal counsel expenses.

     

    The gross proceeds from the Subsequent Offering were approximately $1,500,000 before deducting Univest’s fees and other estimated expenses relating to the Offering. The Company intends to use the net proceeds from the Subsequent Offering on capital expenditures, operating capacity, working capital, general corporate purposes and the refinancing or repayment of existing indebtedness and acquisitions of complementary products, technologies or businesses. 

     

    1 

     

     

    The closing of the Subsequent Offering occurred on May 20, 2024.

     

    Each of the Purchase Agreements includes customary representations, warranties and covenants by the Company and the Purchasers.  Additionally, the Company has agreed to provide the Purchasers with customary indemnification under the Purchase Agreement against certain liabilities, including liabilities under the Securities Act of 1933, as amended.

      

    On May 17, 2024, the Company issued press releases titled “Akanda Corp. Announces Closing of Registered Direct Offering” and “Akanda Corp. Announces Subsequent Registered Direct Offering”, copies of which are furnished herewith as Exhibit 99.1 and Exhibit 99.2 to this Report on Form 6-K.

     

    On May 20, 2024, the Company issued a press release titled “Akanda Corp. Announces Closing of Subsequent Registered Direct Offering”, a copy of which is furnished herewith as Exhibit 99.3 to this Report on Form 6-K.

     

    The descriptions of the Securities Purchase Agreement and Pre-Funded Warrants are only a summary and are qualified in their entirety by reference to the complete text of the form of Securities Purchase Agreement and the form of Pre-Funded Warrants, copies of which are attached as Exhibit 1.1 and Exhibit 4.1 to this Report on Form 6-K and are incorporated by reference herein and into the Company’s registration statement on Form F-3 (File No. 333-276577), which was declared effective as of January 29, 2024 by Securities and Exchange Commission.

     

    The press releases furnished in this report as Exhibit 99.1, 99.2 and 99.3 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.

     

    Exhibit No.   Description
    1.1   Form of Securities Purchase Agreement
    4.1   Form of Pre-Funded Warrant
    5.1   Opinion of Gowling WLG (Canada) LLP
    5.2   Opinion of Gowling WLG (Canada) LLP
    23.1   Consent of Opinion of Gowling WLG (Canada) LLP (set forth in Exhibit 5.1)
    23.2   Consent of Opinion of Gowling WLG (Canada) LLP (set forth in Exhibit 5.2)
    99.1   Press Release, dated May 17, 2024 Announcing Closing of Registered Direct Offering
    99.2   Press Release, dated May 17, 2024 Announcing Pricing of Subsequent Registered Direct Offering
    99.3   Press Release, dated May 20, 2024 Announcing Closing of Subsequent Registered Direct Offering

     

    2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      AKANDA CORP.
      (Registrant)
         
    Date:  May 20, 2024 By: /s/ Katie Field
        Name:  Katie Field
        Title: Interim Chief Executive Officer and Director

     

     

    3

     

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akanda Corp. Announces Reverse Stock Split

    Toronto, Ontario--(Newsfile Corp. - January 8, 2026) - Akanda Corp. (NASDAQ:AKAN) (the "Company" or "Akanda"), today announced that it expects to implement a 1-for-5 reverse stock split of the Company's common shares effective January 12, 2026. The reverse stock split was previously approved by the Company's shareholders on November 28, 2025 and Board of Directors on December 23, 2025 and will begin trading on an adjusted basis giving effect to the reverse stock split at the opening of market on January 12, 2026 under the existing ticker symbol "AKAN". The new CUSIP number of the Company's common shares will be 00971M601 and the new ISIN code will be CA00971M6018.In accordance with the propo

    1/8/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Akanda Corp. Welcomes Momentum Towards Cannabis Reform in the United States

    Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company") applauds the recent reports that US President Donald Trump and his administration are considering changes and the reclassification of federal cannabis policy in the USA, including potential rescheduling of cannabis from Schedule I to Schedule III. Schedule III drugs are considered to have a medical value and a lower abuse potential as defined by the Drug Enforcement Administration."Cannabis policies are long overdue for modernization," said Interim CEO Katie Field. "The US Administration is taking steps to treat cannabis through a science-led, public-health framework which has the

    12/18/25 7:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    RETRANSMISSION: Akanda Researching Security Requirements for Full Cultivation License

    Toronto, Ontario--(Newsfile Corp. - November 14, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company currently operates under its hemp cultivation license, Akanda plans to advance toward a full cultivation license for a range of potential THC products and, in parallel, intends to design and commence the build-out of Health Canada–compliant security measures at the site. This planned security program—anticipated to require enhanced perim

    11/14/25 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AKAN
    SEC Filings

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Hrt Financial Lp claimed ownership of 15,684 units of Class A Shares (SEC Form 3)

    3 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 1:36:34 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form F-1/A filed by Akanda Corp.

    F-1/A - AKANDA CORP. (0001888014) (Filer)

    1/28/26 10:54:22 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form F-1 filed by Akanda Corp.

    F-1 - AKANDA CORP. (0001888014) (Filer)

    1/26/26 5:25:59 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    1/23/26 5:25:16 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Leadership Updates

    Live Leadership Updates

    View All

    Halo Collective Announces Change of Auditors and Failure to File Cease Trade Order

    Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Halo Collective Inc. (NEO: HALO) (OTCQB:HCANF) (FSE: A9K0) ("Halo" or the "Company") announces today that it has changed its auditor (the "Change of Auditor") from Macias Gini & O'Connell LLP (the "Former Auditor") to GreenGrowth CPAs (the "Successor Auditor"). The Former Auditor resigned effective June 19, 2023, and the Company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.There was no modified opinion, or other opinion, issued by the Former Auditor in connection with its audit of the Co

    6/22/23 1:06:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Canmart Ends CEO Service Agreement; Akanda Approves Appointment of Director

    International medical cannabis platform company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk's Service Agreement dated June 2, 2021 (the "Service Agreement") to an immediate end with effect from February 13th, 2023. As disclosed on February 7th, 2023, the Company disclosed Mr. Virk's attempt to end the Service Agreement without providing the requisite period of notice required under the Service Agreement, his interpretation of the Service Agreement, and allegations of Breach of Contract. On February 13th, 2023, the Company informed Mr. Virk that it had reached the conclusion that it has a right to bring the Service

    2/16/23 5:05:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    /R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/

    TORONTO, Aug. 12, 2022 /PRNewswire/ -  Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced the appointment of Katie Field, Chief Executive Officer of Halo, to Chairman of the board of directors of the Company (the "Board"), effective immediately. Current Chairman Ryan Kunkel has resigned from the Board to focus on other professional endeavors. To the knowledge of the Company, Ms. Field is the second woman to serve as Chairman and CEO of a publicly traded cannabis company, the first being Kim Rivers of Trulieve (CSE:TRUL). Ca

    8/12/22 8:00:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Akanda Corp. (Amendment)

    SC 13D/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 6:01:03 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Akanda Corp.

    SC 13D - AKANDA CORP. (0001888014) (Subject)

    2/20/24 5:17:13 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Akanda Corp. (Amendment)

    SC 13G/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 12:55:32 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Financials

    Live finance-specific insights

    View All

    Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon

    TORONTO, Sept. 22, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced, further to its press release dated August 27, 2021, that it has completed the acquisition of all of the substantial assets of three operating entities doing business as Pistil Point in Oregon which collectively hold multiple cannabis licenses. With this transaction, Halo now has full ownership of a range of indoor and outdoor cultivation, manufacturing, and distributions assets, along with an expanded library of genetics that is expected to allow the Company to continue to execute its vertically integrated strategy in Oregon with enhanced compet

    9/22/22 5:00:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Halo Collective Announces Westwood Dispensary Completion, Local Inspections Passed, and Planned Opening for Second Budega™ in California

    TORONTO, April 12, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced that its Budega Westwood Dispensary passed its Los Angeles inspection and is expected to open within 30 days. The Budega Westwood location is perfectly located nestled in between Westwood to the west and Beverly Hills to the east, right off of one of LA's most traveled and famous thoroughfares for locals and visitors, the Santa Monica Boulevard (10461 Santa Monica Blvd) and within two miles of the University of Los Angeles California campus. The facility is leased and near complete with renovations of its approximately 1,500 square foot prime retail

    4/12/22 4:40:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care